The use of antibodies in small-molecule drug discovery

Journal of Biomolecular Screening

Volumn 19, Issue 6, 2014, Pages 829-838

  Marsden, Catherine J ^a   Eckersley, Sonia ^a   Hebditch, Max ^a   Kvist, Alexander J ^a   Milner, Roy ^a   Mitchell, Danielle ^a   Warwicker, Juli ^a   Marley, Anna E ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

antibody tool; crystallization chaperone; drug discovery; phenotypic screening; review; target validation

Indexed keywords

ANTIBODY; G PROTEIN COUPLED RECEPTOR; CHAPERONE; EPITOPE; IMMUNOGLOBULIN G; RNA; PROTEIN DERIVATIVE;

ANTIBODY AFFINITY; ANTIBODY LIBRARY; CELLULAR DISTRIBUTION; DRUG DEVELOPMENT; GEL ELECTROPHORESIS; HIGH THROUGHPUT SCREENING; HUMAN; IN VIVO STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEOMICS; REVIEW; RNA INTERFERENCE; ANIMAL; CHEMISTRY; CRYSTALLIZATION; PHENOTYPE; PROCEDURES; TRANSGENIC ANIMAL; ANTIGEN BINDING; DRUG SCREENING; NONHUMAN;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES; ANTIBODY AFFINITY; CRYSTALLIZATION; DRUG DISCOVERY; EPITOPES; HUMANS; IMMUNOGLOBULIN G; MOLECULAR CHAPERONES; PHENOTYPE; PROTEIN ENGINEERING; PROTEOMICS; RNA;

EID: 84904885588     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114527770     Document Type: Review

References (98)

1. Mehan M. R., Ostroff R., Wilcox S. K., et al. Highly Multiplexed Proteomic Platform for Biomarker Discovery, Diagnostics, and Therapeutics. Adv. Exp. Med. Biol. 2013 ; 735: 283-300
2. Rust S., Guillard S., Sachsenmeier K., et al. Combining Phenotypic and Proteomic Approaches to Identify Membrane Targets in a 'Triple Negative' Breast Cancer Cell Type. Mol. Cancer. 2013 ; 12: 11
3. Griffin L., Lawson A.. Antibody Fragments as Tools in Crystallography. Clin. Exp. Immunol. 2011 ; 165: 285-289
4. Lawson A. D.. Antibody Enabled Small Molecule Drug Discovery. Nat. Rev. 2012 ; 11: 519-525
5. Abdellah Z., Ahmadi A., Ahmed S., et al. Finishing the Euchromatic Sequence of the Human Genome. Nature. 2004 ; 431: 931-945
6. Knox C., Law V., Jewison T.. DrugBank 3.0: A Comprehensive Resource for 'Omics' Research on Drugs. Nucleic Acids Res. 2011 ; 39 :
7. Hanash S. M., Gurpide J.-M., Misek D. E.. Identification of Novel Targets for Cancer Therapy Using Expression Proteomics. Leukemia. 2002 ; 16: 478-485 (Pubitemid 34449727)
8. Keshishian H., Addona T., Burgess M., et al. Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution. Mol. Cell. Proteomics. 2007 ; 6: 2212-2229
9. Picotti P., Bodenmiller B., Aebersol R.. Proteomics Meets the Scientific Method. Nat. Method. 2013 ; 10: 24-27
10. Haab B.. Applications of antibody array platforms. Curr. Opin. Biotech. 2006 ; 17: 415-421 (Pubitemid 44163462)
11. Aldred S., Grant M., Griffiths H.. The Use of Proteomics for the Assessment of Clinical Samples in Research. Clin. Biochem. 2004 ; 37: 943-952 (Pubitemid 39388654)
12. Schwenk J. M., Igel U., Neiman M., et al. Toward Next Generation Plasma Profiling via Heat-Induced Epitope Retrieval and Array-Based Assay. Mol. Cell. Proteomics. 2010 ; 9: 2497-2507
13. Kohler K., Seitz H.. Validation Processes of Protein Biomarkers in Serum - A Cross Platform Comparison. Sensors. 2012 ; 12: 12710-12728
14. Kierny R. M., Cunningham T. D., Kay B. K.. Detection of Biomarkers Using Recombinant Antibodies Coupled to Nanostructured Platforms. Nano Rev. 2012 ; 3: 17240
15. Birtwell S., Morgan H.. Microparticle Encoding Technologies for High-Throughput Multiplexed Suspension Assays. Integer. Biol. 2009 ; 1: 345-362
16. Sanchez-Carboayo M.. Antibody Arrays: Technical Considerations and Clinical Applications in Cancer. Clin. Chem. 2006 ; 52: 1651-1659
17. Ingvarsson J., Wingren C., Carlsson A., et al. Detection of Pancreatic Cancer Using Antibody Microarray-Based Serum Protein Profiling. Proteomics. 2008 ; 8: 2211-2219 (Pubitemid 351898027)
18. Carlsson A., Wingrena C., Ingvarsson J., et al. Serum Proteome Profiling of Metastatic Breast Cancer Using Recombinant Antibody Microarrays. Eur. J. Cancer. 2008 ; 44: 472-480 (Pubitemid 351179627)
19. Zhang D., Ye F., Ling Gao L.. Proteomics, Pathway Array and Signaling Network-Based Medicine in Cancer. Cell Division. 2009 ; 4: 20
20. Mahlknecht P., Stemberger S., Sprenger F., et al. An Antibody Microarray Analysis of Serum Cytokines in Neurodegenerative Parkinsonian Syndromes. Proteome Sci. 2012 ; 10: 71
21. Borrebaeck C., Wingren C.. Design of High-Density Antibody Microarrays for Disease Proteomics: Key Technological Issues. J. Proteomics. 2009 ; 72: 928-935
22. Holm A., Wu W., Lund-Johansen F.. Antibody Array Analysis of Labelled Proteomes: How Should We Control Specificity?. New Biotechnol. 2012 ; 29: 578-585
23. Asplund A., Edqvist P. D., Schwenk J. M., Pontén F.. Antibodies for Profiling the Human Proteome: The Human Protein Atlas as a Resource for Cancer Research. Proteomics. 2012 ; 12: 2067-2077
24. Anderson N. L., Anderson N. G., Haines L. R., et al. Mass Spectrometric Quantitation of Peptides and Proteins Using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J. Proteome Res. 2004 ; 3: 235-244 (Pubitemid 38500990)
25. Anderson N. L., Jackson A., Smith D., et al. SISCAPA Peptide Enrichment on Magnetic Beads Using an In-line Bead Trap Device. Mol. Cell. Proteomics. 2009 ; 8: 995-1005
26. Hanash S. M., Madoz-Gurpide J., Misek D. E.. Identification of Novel Targets for Cancer Therapy Using Expression Proteomics. Leukemia. 2002 ; 16: 478-485 (Pubitemid 34449727)
27. Hughes J. P., Rees S., Kalindjian S. B., Philpott K. L.. Principles of Early Drug Discovery. Br. J. Pharmacol. 2011 ; 162: 1239-12349
28. Dunne A., Jowett M., Rees S.. Use of Primary Human Cells in High-Throughput Screens. Methods Mol. Biol. 2009 ; 565: 239-257
29. Dove A.. Screening for Content: The Evolution of High Throughput. Nat. Biotechnol. 2003 ; 21: 859-864 (Pubitemid 36936186)
30. Swinney D. C., Anthony J.. How Were New Medicines Discovered?. Nat. Rev. Drug Discov. 2011 ; 10: 507-519
31. Clemons P. A.. Complex Phenotypic Assays in High-Throughput Screening. Curr. Opin. Chem. Biol. 2004 ; 8: 334-338 (Pubitemid 38759409)
32. Thomas N.. High-Content Screening: A Decade of Evolution. J. Biomol. Screen. 2010 ; 15: 1-9
33. Sykes M., Avery V.. Approaches to Protozoan Drug Discovery: Phenotypic Screening. J. Med. Chem. 2013 ; 56: 7727-7740
34. Figuera-Losada M., Rojas C., Slusher B.. Inhibition of Microglia Activation as a Phenotypic Assay in Early Drug Discovery. J. Biomol. Screen. 2014 ; 19: 17-31
35. Zhang M., Luo G., Zhou Y., et al. Phenotypic Screens Targeting Neurodegenerative Diseases. J. Biomol. Screen. 2014 ; 19: 1-16
36. Kurosawaa G., Akahoria Y., Morita M., et al. Comprehensive Screening for Antigens Overexpressed on Carcinomas via Isolation of Human mAbs That May Be Therapeutic. Proc. Natl. Acad. Sci. U.S.A. 2008 ; 105: 7287-7292 (Pubitemid 351754470)
37. Zhang H., Wilson I. A., Lerner R. A.. Selection of Antibodies That Regulate Phenotype from Intracellular Combinatorial Antibody Libraries. Proc. Natl. Acad. Sci. U.S.A. 2012 ; 109: 15728-15733
38. Zhang H., Yea K., Xie J., Ruiz D., Wilson I., Lerner R.. Selecting Agonists from Single Cells Infected with Combinatorial Antibody Libraries. Chem. Biol. 2013 ; 20: 734-741
39. Helmuth H., Gert-Jan A.. Biology Calls the Targets: Combining RNAi and Disease Biology. Drug Discov. Today. 2005 ; 20: 1385-1391
40. Gondo Y.. Now and Future of Mouse Mutagenesis for Human Disease Models. J. Genet. Genomics. 2012 ; 37: 559-572
41. Arrowsmith J.. Trial Watch: Phase II Failures: 2008-2010. Nat. Rev. Drug Discov. 2011 ; 10: 328-329
42. Loven J., Orland D.A., Sigova A. A., et al. Revisiting Global Gene Expression Analysis. Cell. 2012 ; 151: 476-482
43. Rhodes K., Trimmer J.. Antibody-Based Validation of CNS Ion Channel Drug Targets. J. Gen. Physiol. 2008 ; 131: 407-413 (Pubitemid 351620097)
44. Fredriksson S., Gullberg M., Jarvius J., et al. Protein Detection Using Proximity-Dependent DNA Ligation Assays. Nat. Biotechnol. 2002 ; 20: 473-477 (Pubitemid 34495933)
45. Weibrecht I., Leuchowius K.-J., Clausson C.-M., et al. Proximity Ligation Assays: A Recent Addition to the Proteomics Toolbox. Expert Rev. Proteomics. 2010 ; 7: 401-409
46. Ke R., Nong R. Y., Fredreiksson S., et al. Improving Precision of Proximity Ligation Assay by Amplified Single Molecule Detection. PLOS One. 2013 ; 8: 1-5
47. Gu G., Wu D., Lund H., et al. Elevated MARK2-Dependent Phosphorylation of Tau in Alzheimer's Disease. J Alzheimers Dis. 2012 ; 33: 699-713
48. Geyer C., McCafferty J., Dübel S., et al. Recombinant Antibodies and In Vitro Selection Technologies. Methods Mol. Biol. 2012 ; 901: 11-32
49. Cudic M., Fields G. B.. Extracellular Proteases as Targets for Drug Development. Curr. Protein Pept. Sci. 2009 ; 10: 297-307
50. Ganesan R., Eigenbrot C., Wu Y., et al. Unraveling the Allosteric Mechanism of Serine Protease Inhibition by an Antibody. Structure. 2009 ; 17: 1614-1624
51. Overington J. P., Al-Lazikani B., Hopkins A. L.. How Many Drug Targets Are There?. Nat. Rev. Drug Discov. 2006 ; 5: 993-996 (Pubitemid 44835126)
52. Naylor J., Beech D.. Extracellular Ion Channel Inhibitor Antibodies. Open Drug Discov. J. 2009 ; 1: 36-42
53. Riquelme M. A., Kar R., Gu S., et al. Antibodies Targeting Extracellular Domain of Connexins for Studies of Hemichannels. Neuropharmacology. 2013 ; 75: 525-532
54. Wayner E. A., Hoffstrom B. C.. Development of Monoclonal Antibodies to Integrin Receptors. Methods Enzymol. 2007 ; 426: 117-153
55. Gupta A., Heimann A., Gomes I., et al. Antibodies against G-Protein Coupled Receptors: Novel Uses in Screening and Drug Development. Comb. Chem. High Throughput Screen. 2008 ; 11: 463-467 (Pubitemid 351969362)
56. Gupta A., Decaillot F., Gomes I., et al. Conformation State-Sensitive Antibodies to G-Protein-Coupled Receptors. J. Biol. Chem. 2007 ; 282: 5116-5124 (Pubitemid 47093768)
57. Ullmer C., Zoffmann S., Bohrmann B., et al. Functional Monoclonal Antibody Acts as a Biased Agonist by Inducing Internalization of Metabotropic Glutamate Receptor 7. Br. J. Pharmacol. 2012 ; 167: 1448-1466
58. Michel M. C., Wieland T., Tsujimoto G.. How Reliable Are G-Protein-Coupled Receptor Antibodies?. Naunyn-Schmiedeberg's Arch. Pharmacol. 2009 ; 379: 385-388
59. Webb D., Handel T., Kretz-Rommel A., et al. Opportunities for Functional Selectivity in GPCR Antibodies. Biochem. Pharmacol. 2013 ; 15: 147-152
60. Molek P., Strukelj B., Bratkovic T.. Peptide Phage Display as a Tool for Drug Discovery: Targeting Membrane Receptors. Molecules. 2011 ; 16: 857-887
61. Uhlen M., Ponten F.. Antibody-Based Proteomics for Human Tissue Profiling. Mol. Cell. Proteomics. 2005 ; 4: 384-393 (Pubitemid 40590558)
62. Manikandan J., Pushparaj P. N., Melendez A. J.. Protein Interference at Protein Level by Intrabodies. Front. Biosci. 2007 ; 12: 1344-1352
63. Shaki-Loewensteina S., Zfaniaa R., Hyland S., et al. A Universal Strategy for Stable Intracellular Antibodies. J. Immunol. Methods. 2005 ; 303: 19-39 (Pubitemid 41169943)
64. Ewert S., Honegger A., Plückthun A.. Stability Improvement of Antibodies for Extracellular and Intracellular Applications: CDR Grafting to Stable Frameworks and Structure-Based Framework Engineering. Methods. 2004 ; 34: 184-199 (Pubitemid 39092813)
65. Stocks M.. Intrabodies as Drug Discovery Tools and Therapeutics. Curr. Opin. Chem. Biol. 2005 ; 9: 359-365 (Pubitemid 41019681)
66. Haque A., Andersen J. N., Salmeen A., et al. Conformation-Sensing Antibodies Stabilize the Oxidized Form of PTP1B and Inhibit Its Phosphatase Activity. Cell. 2011 ; 147: 185-198
67. Donini M., Morea V., Desiderio A., et al. Engineering Stable Cytoplasmic Intrabodies with Designed Specificity. J. Mol. Biol. 2003 ; 330: 323-332 (Pubitemid 36773705)
68. Cohen P. A., Mani J. C., Lane D. P.. Characterization of a New Intrabody Directed against the N-Terminal Region of Human p53. Oncogene. 1998 ; 17: 2445-2456 (Pubitemid 28544714)
69. Muyldermans S.. Nanobodies-Natural Single Domain Antibodies. Annu. Rev. Biochem. 2013 ; 82: 775-797
70. Parizek P., Kummer L., Rube P., et al. Designed Ankyrin Repeat Proteins (DARPins) as Novel Isoform-Specific Intracellular Inhibitors of c-Jun N-Terminal Kinases. ACS Chem. Biol. 2012 ; 7: 1356-1366
71. Irannejad R., Tomshine J. C., Tomshine J. R., et al. Conformational Antibody Biosensors Reveal GPCR Signalling from Endosomes. Nature. 2013 ; 495: 534-540
72. Stumpp M. T., Amstutz P.. DARPins: A True Alternative to Antibodies. Curr. Opin. Drug Discov. Devel. 2007 ; 10: 153-159 (Pubitemid 46438644)
73. Kawe M., Forrer P., Amstutz P., et al. Isolation of Intracellular Proteinase Inhibitors Derived from Designed Ankyrin Repeat Proteins by Genetic Screening. J. Biol. Chem. 2006 ; 281: 40252-40263 (Pubitemid 46041830)
74. Boersma Y. L., Chao G., Steiner D., et al. Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling. J. Biol. Chem. 2011 ; 286: 41273-41285
75. Binz H. K., Stumpp M. T., Forrer P., et al. Designing Repeat Proteins: Well-Expressed, Soluble and Stable Proteins from Combinatorial Libraries of Consensus Ankyrin Repeat Proteins. J. Mol. Biol. 2003 ; 332: 489-503 (Pubitemid 37020959)
76. Blundell T. L., Patel S.. High-Throughput X-Ray Crystallography for Drug Discovery. Curr. Opin. Pharmacol. 2004 ; 4: 490-496 (Pubitemid 40533010)
77. Chayen N., Saridakis E.. Protein Crystallization: From Purified Protein to Diffraction Quality Crystal. Nat. Methods. 2008 ; 5: 147-153 (Pubitemid 351181740)
78. Pai J. C., Culver J. A., Drury J. E., et al. Conversion of scFv Peptide-Binding Specificity for Crystal Chaperone Development. Protein Eng. Des. Sel. 2011 ; 24: 419-428
79. Lim H.-H., Fang Y., Williams C.. High-Efficiency Screening of Monoclonal Antibodies for Membrane Protein Crystallography. PloS One. 2011 ; 6: e24653
80. Griffin L., Lawson A.. Antibody Fragments as Tools in Crystallography. Clin. Exp. Immunol. 2011 ; 165: 285-291
81. Sheriff S., Constantine K.. Redefining the Minimal Antigen-Binding Fragment. Nat. Struct. Mol. Biol. 1996 ; 3: 733-736 (Pubitemid 26303395)
82. Wu M., Park Y., Pardon E., et al. Structures of a Key Interaction Protein from the Trypanosoma brucei Editosome in Complex with Single Domain Antibodies. J. Struct. Biol. 2011 ; 174: 124-136
83. Grisshammer R.. Purification of Recombinant G-Protein-Coupled Receptors. Methods Enzymol. 2009 ; 463: 631-645
84. Rasmussen S., Choi H., Fung J.. Structure of a Nanobody-Stabilized Active State of the β2 Adrenoceptor. Nature. 2011 ; 469: 175-180
85. Garland S.. Are GPCRs Still a Source of New Targets?. J. Biomol. Screen. 2013 ; 18: 947-966
86. Domanska K., Vanderhaegen S., Srinivasan V., et al. Atomic Structure of a Nanobody-Trapped Domain-Swapped Dimer of an Amyloidogenic Beta2-Microglobulin Variant. Proc. Natl. Acad. Sci. U.S.A. 2011 ; 108: 1314-1319
87. Jones S., Smith D. P., Radford S. E.. Role of the N and C-Terminal Strands of Beta 2-Microglobulin in Amyloid Formation at Neutral pH. J. Mol. Biol. 2003 ; 330: 935-941 (Pubitemid 36818892)
88. Tereshko V., Uysal S., Koide A., et al. Toward Chaperone-Assisted Crystallography: Protein Engineering Enhancement of Crystal Packing and Xray Phasing Capabilities of a Camelid Single Domain Antibody (VHH). Protein Sci. 2008 ; 17: 1175-1187 (Pubitemid 351930915)
89. Wang N., Majmudar C. Y., Pomerantz W. C., et al. Ordering a Dynamic Protein via a Small-Molecule Stabilizer. J. Am. Chem. Soc. 2013 ; 135: 3363-3366
90. Couchman J. R.. Commercial Antibodies: The Good, Bad, and Really Ugly. J. Histochem. Cytochem. 2009 ; 57: 7-8
91. Bordeaux J., Welsh A., Agarwal S., et al. Antibody Validation. BioTechniques. 2010 ; 48: 197-209
92. Milner R., Wombwell H., Eckersley S., et al. Validation of the BRCA1 Antibody MS110 and the Utility of BRCA1 as a Patient Selection Biomarker in Immunohistochemical Analysis of Breast and Ovarian Tumours. Virchows Arch. 2013 ; 462: 269-279
93. Affinomics. http://www.affinomics.org/.
94. NCI Antibody Characterisation Programme. http://antibodies.cancer.gov/ apps/site/characterization-process/.
95. National Institutes of Health. Protein Capture. http://commonfund.nih. gov/proteincapture/.
96. Human Protein Atlas. http://www.proteinatlas.org/.
97. Human Proteome Organisation. http://www.hupo.org/.
98. Recombinant Antibody Network. http://ran.uchicago.edu/.